APOL1 and kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 179-182

  Pollak, Martin R ^a   Genovese, Giulio ^a   Friedman, David J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

African American; APOL1; apolipoprotein L1; FSGS; HIV nephropathy

Indexed keywords

AFRICAN AMERICAN; AFRICAN TRYPANOSOMIASIS; APOLIPOPROTEIN L1 GENE; CHROMOSOME 22; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; FOCAL GLOMERULOSCLEROSIS; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MYH9 GENE; NEPHROLOGIST; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRYPANOSOMA BRUCEI; TRYPANOSOMA RHODESIENSE;

AFRICAN AMERICANS; AIDS-ASSOCIATED NEPHROPATHY; APOLIPOPROTEINS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; HYPERTENSION; KIDNEY DISEASES; LIPOPROTEINS, HDL;

EID: 84857064298     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835012ab     Document Type: Review

References (25)

1. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
2. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175-1184.
3. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic endstage renal disease in African Americans. Nat Genet 2008; 40:1185-1192.
4. Genovese G, Tonna SJ, Knob AU, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010; 78:698-704.
5. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128:345-350. See ref [6 ].
6. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841-845. demonstrated that APOL1 variants associate with kidney disease in African Americans.
7. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-Associated nephropathy. J Am Soc Nephrol 2011; 22:2129-2137. This report defines the risk for HIV nephropathy and FSGS conferred by APOL1 variants.
8. Friedman DJ, Kozlitina J, Genovese G, et al. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011; 22:2098-2105. This study analyzed APOL1 genotype in participants in the Dallas Heart Study, showing that most of the excess risk for nondiabetic renal disease in African Americans is due to APOL1 variants.
9. Papeta N, Kiryluk K, Patel A, et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011; 22:1991-1996. This study shows that APOL1 variants increase the risk of FSGS but not of IgA nephropathy.
10. Duchateau PN, Pullinger CR, Orellana RE, et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 1997; 272:25576-25582. (Pubitemid 27438869)
11. Wan G, Zhaorigetu S, Liu Z, et al. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem 2008; 283:21540-21549.
12. Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJ. The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics 2002; 79:539-546. (Pubitemid 34274295)
13. Smith EE,Malik HS. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res 2009; 19:850-858.
14. Pays E, Vanhollebeke B. Mutual self-defence: The trypanolytic factor story. Microbes Infect/Institut Pasteur 2008; 10:985-989.
15. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005; 309:469-472. (Pubitemid 40994686)
16. Pays E, Vanhollebeke B, Vanhamme L, et al. The trypanolytic factor of human serum. Nat Rev Microbiol 2006; 4:477-486. (Pubitemid 43771867)
17. Lecordier L, Vanhollebeke B, Poelvoorde P, et al. C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS Pathog 2009; 5:e1000685.
18. Kanji Z, Powe CE, Wenger JB, et al. Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol 2011; 22:2091-2097.
19. Zhaorigetu S, Wan G, Kaini R, et al. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 2008; 4:1079-1082.
20. Madhavan SM, O'Toole JF, Konieczkowski M, et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011; 22:2119-2128. This study defined the pattern of ApoL1 staining in healthy and diseased human kidney.
21. Reeves-Daniel AM, Depalma JA, Bleyer AJ, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11:1025-1030. This study suggests that kidneys transplanted from high-risk APOL1 genotype deceased donors are more likely to fail early.
22. Cooke JN, Bostrom MA, Hicks PJ, et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans. Nephrol Dial Transplant 2011. [Epub ahead of print].
23. O'Seaghdha CM, Parekh RS, Hwang SJ, et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 2011; 20:2450-2456. This article and [22 ] suggest that variation in MYH9 may have a small independent effect on risk of kidney disease in European Americans.
24. Han KH, Lee H, Kang HG, et al. Renal manifestations of patients with MYH9-related disorders. Pediatr Nephrol 2011; 26:549-555.
25. Appel LJ, Wright JT Jr., Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918-929.